Faron Pharmaceuticals Oy (LSE:FARN) Total Liabilities : £21.87 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Total Liabilities?

Faron Pharmaceuticals Oy's Total Liabilities for the quarter that ended in Dec. 2023 was £21.87 Mil.

Faron Pharmaceuticals Oy's quarterly Total Liabilities declined from Dec. 2022 (£19.78 Mil) to Jun. 2023 (£19.15 Mil) but then increased from Jun. 2023 (£19.15 Mil) to Dec. 2023 (£21.87 Mil).

Faron Pharmaceuticals Oy's annual Total Liabilities increased from Dec. 2021 (£8.72 Mil) to Dec. 2022 (£19.78 Mil) and increased from Dec. 2022 (£19.78 Mil) to Dec. 2023 (£21.87 Mil).

Faron Pharmaceuticals Oy Total Liabilities Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Total Liabilities Chart

Faron Pharmaceuticals Oy Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

7.29

9.25

8.72

19.78

21.87

Faron Pharmaceuticals Oy Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															8.72	18.82	19.78	19.15	21.87

Faron Pharmaceuticals Oy Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Faron Pharmaceuticals Oy's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	12.933	+	(8.161	+	0.772
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	21.87

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	8.805	-	-13.061
	=	21.87

Faron Pharmaceuticals Oy's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	12.933	+	(8.161	+	0.772
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	21.87

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	8.805	-	-13.061
	=	21.87

Faron Pharmaceuticals Oy Total Liabilities Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

FARON:Finland 4FR:Germany

Address

Joukahaisenkatu 6 B, Turku, FIN, 20520

Website

https://www.faron.com

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines